Unknown

Dataset Information

0

Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses.


ABSTRACT: This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection. A prophylactic vaccine with efficacy against acquisition (VES) ?70% can eliminate the infection. A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity. At VES of 50%, the number of vaccinated persons needed to avert one infection is 2.4, and the number is 25.5 to avert one severe disease case, 33.2 to avert one critical disease case, and 65.1 to avert one death. The probability of a major outbreak is zero at VES ?70% regardless of the number of virus introductions. However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact. In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact.

SUBMITTER: Makhoul M 

PROVIDER: S-EPMC7712303 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses.

Makhoul Monia M   Ayoub Houssein H HH   Chemaitelly Hiam H   Seedat Shaheen S   Mumtaz Ghina R GR   Al-Omari Sarah S   Abu-Raddad Laith J LJ  

Vaccines 20201109 4


This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection. A prophylactic vaccine with efficacy against acquisition (<i>VE</i><sub>S</sub>) ≥70% can eliminate the infection. A vaccine with <i>VE</i><sub>S</sub> <70% may still control the infection if it reduces infectiousness or infec  ...[more]

Similar Datasets

| S-EPMC7564812 | biostudies-literature
| S-EPMC7591473 | biostudies-literature
| S-EPMC9088668 | biostudies-literature
| S-EPMC7897910 | biostudies-literature
| S-EPMC9053258 | biostudies-literature
2016-03-16 | E-GEOD-79208 | biostudies-arrayexpress
| S-EPMC8960902 | biostudies-literature
2016-03-16 | GSE79208 | GEO
| S-EPMC6122803 | biostudies-other
| S-EPMC8647717 | biostudies-literature